Aballéa S - Search Results

1

rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B: Post hoc analysis of B-LONG using haemophilia-specific quality of life questionnaires.

Astermark J, Hermans C, Ezzalfani M, Aballéa S, Santagostino E, Hakimi Z, Nazir J. Astermark J, et al. Among authors: aballea s. Haemophilia. 2022 Jan;28(1):18-26. doi: 10.1111/hae.14455. Epub 2021 Nov 10. Haemophilia. 2022. PMID: 34761474

2

Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder.

Desroziers K, Aballéa S, Maman K, Nazir J, Odeyemi I, Hakimi Z. Desroziers K, et al. Among authors: aballea s. Health Qual Life Outcomes. 2013 Nov 19;11:200. doi: 10.1186/1477-7525-11-200. Health Qual Life Outcomes. 2013. PMID: 24246044 Free PMC article.

3

Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.

Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, Odeyemi I, Hakimi Z. Maman K, et al. Among authors: aballea s. Eur Urol. 2014 Apr;65(4):755-65. doi: 10.1016/j.eururo.2013.11.010. Epub 2013 Nov 18. Eur Urol. 2014. PMID: 24275310 Review.

4

Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom.

Aballéa S, Maman K, Thokagevistk K, Nazir J, Odeyemi IA, Hakimi Z, Garnham A, Toumi M. Aballéa S, et al. Clin Drug Investig. 2015 Feb;35(2):83-93. doi: 10.1007/s40261-014-0240-z. Clin Drug Investig. 2015. PMID: 25491433 Free PMC article. Clinical Trial.

5

Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.

Nazir J, Maman K, Neine ME, Briquet B, Odeyemi IA, Hakimi Z, Garnham A, Aballéa S. Nazir J, et al. Among authors: aballea s. Value Health. 2015 Sep;18(6):783-90. doi: 10.1016/j.jval.2015.05.011. Epub 2015 Sep 9. Value Health. 2015. PMID: 26409605 Free article.

6

Comparative Efficacy And Tolerability Of Solifenacin 5mg Versus Oral Antimuscarinic Agents In Overactive Bladder (Oab): A Systematic Literature Review (Slr) And Mixed Treatment Comparison (Mtc).

Kelleher C, Aballea S, Maman K, Nazir J, Hakimi Z, Chambers C, Odeyemi IA. Kelleher C, et al. Among authors: aballea s. Value Health. 2014 Nov;17(7):A466. doi: 10.1016/j.jval.2014.08.1309. Epub 2014 Oct 26. Value Health. 2014. PMID: 27201324 Free article. No abstract available.

7

Cost Effectiveness Of Solifenacin Compared With Oral Antimuscarinic Agents For The Treatment Of Patients With Overactive Bladder (Oab) In The Uk.

Kelleher C, Aballea S, Maman K, Nazir J, Hakimi Z, Chambers C, Odeyemi IA. Kelleher C, et al. Among authors: aballea s. Value Health. 2014 Nov;17(7):A469. doi: 10.1016/j.jval.2014.08.1324. Epub 2014 Oct 26. Value Health. 2014. PMID: 27201339 Free article. No abstract available.

8

Burden of cytomegalovirus disease in solid organ transplant recipients: a national matched cohort study in an inpatient setting.

Hakimi Z, Aballéa S, Ferchichi S, Scharn M, Odeyemi IA, Toumi M, Saliba F. Hakimi Z, et al. Among authors: aballea s. Transpl Infect Dis. 2017 Oct;19(5). doi: 10.1111/tid.12732. Epub 2017 Jul 21. Transpl Infect Dis. 2017. PMID: 28599091

9

Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis.

Nazir J, Kelleher C, Aballéa S, Maman K, Hakimi Z, Mankowski C, Odeyemi I. Nazir J, et al. Among authors: aballea s. Neurourol Urodyn. 2018 Mar;37(3):986-996. doi: 10.1002/nau.23413. Epub 2017 Nov 15. Neurourol Urodyn. 2018. PMID: 29140559

10

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK.

Hakimi Z, Kelleher C, Aballéa S, Maman K, Nazir J, Mankowski C, Odeyemi I. Hakimi Z, et al. Among authors: aballea s. J Mark Access Health Policy. 2018 Mar 20;6(1):1438721. doi: 10.1080/20016689.2018.1438721. eCollection 2018. J Mark Access Health Policy. 2018. PMID: 29686801 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

109 results

Search Page